171 results
Page 5 of 9
8-K
EX-99.1
m926uht
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
8-K
fbpubz3vscdr8wsieoui
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
090kk1vk kiq0
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
jyxpd224
8 Mar 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma
7:05am
8-K
1qpkffy1xnq4k
2 Mar 21
Regulation FD Disclosure
8:00am
8-K
EX-10.1
b42j zuaz6sj1o0j
16 Feb 21
Entry into a Material Definitive Agreement
7:10am
424B5
z5fv5s 6tsl9p
16 Feb 21
Prospectus supplement for primary offering
7:05am
8-K
EX-99.1
dipx5 859x
4 Jan 21
Aravive Announces Board Member Transition to Advisory Role
4:11pm
8-K
qf9uzm1d7exla 14t4t
19 Nov 20
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-10.1
klag7fawwm
10 Nov 20
Entry into a Material Definitive Agreement
7:10am
8-K
we0yq63fx 1ofjb4e77
8 Oct 20
Regulation FD Disclosure
5:01pm